9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
The molecular mechanisms of resistance to immune checkpoint therapy remain elusive. Here, the authors perform immunogenomic analysis of TCGA data and data from clinical trials for antiPD-1/PD-L1 therapy and highlight the association of 9p21 loss with a cold tumor microenvironment and resistance to t...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f000b69e3fbd4f02bc414de145aab9e8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f000b69e3fbd4f02bc414de145aab9e8 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f000b69e3fbd4f02bc414de145aab9e82021-12-02T17:27:20Z9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy10.1038/s41467-021-25894-92041-1723https://doaj.org/article/f000b69e3fbd4f02bc414de145aab9e82021-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-25894-9https://doaj.org/toc/2041-1723The molecular mechanisms of resistance to immune checkpoint therapy remain elusive. Here, the authors perform immunogenomic analysis of TCGA data and data from clinical trials for antiPD-1/PD-L1 therapy and highlight the association of 9p21 loss with a cold tumor microenvironment and resistance to therapy.Guangchun HanGuoliang YangDapeng HaoYang LuKyaw TheinBenjamin S. SimpsonJianfeng ChenRyan SunOmar AlhalabiRuiping WangMinghao DangEnyu DaiShaojun ZhangFengqi NieShuangtao ZhaoCharles GuoAmeer HamzaBogdan CzerniakChao ChengArlene Siefker-RadtkeKrishna BhatAndrew FutrealGuang PengJennifer WargoWeiyi PengHumam KadaraJaffer AjaniCharles SwantonKevin LitchfieldJordi Rodon AhnertJianjun GaoLinghua WangNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-19 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Guangchun Han Guoliang Yang Dapeng Hao Yang Lu Kyaw Thein Benjamin S. Simpson Jianfeng Chen Ryan Sun Omar Alhalabi Ruiping Wang Minghao Dang Enyu Dai Shaojun Zhang Fengqi Nie Shuangtao Zhao Charles Guo Ameer Hamza Bogdan Czerniak Chao Cheng Arlene Siefker-Radtke Krishna Bhat Andrew Futreal Guang Peng Jennifer Wargo Weiyi Peng Humam Kadara Jaffer Ajani Charles Swanton Kevin Litchfield Jordi Rodon Ahnert Jianjun Gao Linghua Wang 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy |
| description |
The molecular mechanisms of resistance to immune checkpoint therapy remain elusive. Here, the authors perform immunogenomic analysis of TCGA data and data from clinical trials for antiPD-1/PD-L1 therapy and highlight the association of 9p21 loss with a cold tumor microenvironment and resistance to therapy. |
| format |
article |
| author |
Guangchun Han Guoliang Yang Dapeng Hao Yang Lu Kyaw Thein Benjamin S. Simpson Jianfeng Chen Ryan Sun Omar Alhalabi Ruiping Wang Minghao Dang Enyu Dai Shaojun Zhang Fengqi Nie Shuangtao Zhao Charles Guo Ameer Hamza Bogdan Czerniak Chao Cheng Arlene Siefker-Radtke Krishna Bhat Andrew Futreal Guang Peng Jennifer Wargo Weiyi Peng Humam Kadara Jaffer Ajani Charles Swanton Kevin Litchfield Jordi Rodon Ahnert Jianjun Gao Linghua Wang |
| author_facet |
Guangchun Han Guoliang Yang Dapeng Hao Yang Lu Kyaw Thein Benjamin S. Simpson Jianfeng Chen Ryan Sun Omar Alhalabi Ruiping Wang Minghao Dang Enyu Dai Shaojun Zhang Fengqi Nie Shuangtao Zhao Charles Guo Ameer Hamza Bogdan Czerniak Chao Cheng Arlene Siefker-Radtke Krishna Bhat Andrew Futreal Guang Peng Jennifer Wargo Weiyi Peng Humam Kadara Jaffer Ajani Charles Swanton Kevin Litchfield Jordi Rodon Ahnert Jianjun Gao Linghua Wang |
| author_sort |
Guangchun Han |
| title |
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy |
| title_short |
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy |
| title_full |
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy |
| title_fullStr |
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy |
| title_full_unstemmed |
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy |
| title_sort |
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/f000b69e3fbd4f02bc414de145aab9e8 |
| work_keys_str_mv |
AT guangchunhan 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT guoliangyang 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT dapenghao 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT yanglu 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT kyawthein 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT benjaminssimpson 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT jianfengchen 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT ryansun 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT omaralhalabi 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT ruipingwang 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT minghaodang 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT enyudai 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT shaojunzhang 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT fengqinie 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT shuangtaozhao 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT charlesguo 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT ameerhamza 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT bogdanczerniak 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT chaocheng 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT arlenesiefkerradtke 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT krishnabhat 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT andrewfutreal 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT guangpeng 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT jenniferwargo 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT weiyipeng 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT humamkadara 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT jafferajani 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT charlesswanton 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT kevinlitchfield 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT jordirodonahnert 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT jianjungao 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT linghuawang 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy |
| _version_ |
1718380764430598144 |